A Multicenter, Follow-Up Study to Assess Long-Term Electrophysiologic and Clinical Outcomes in Subjects Previously Enrolled in Study 215ON201
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2017
At a glance
- Drugs Opicinumab (Primary)
- Indications Optic neuritis
- Focus Pharmacodynamics
- Acronyms RENEWed
- Sponsors Biogen
- 24 Feb 2017 Status changed from recruiting to completed.
- 17 Feb 2017 This trial has been completed in Hungary (end date: 2017-01-23).
- 23 Jan 2017 Planned End Date changed from 1 Feb 2017 to 1 Jan 2017.